Evidence map›Paper›PMID 29265379›Full record

Trial reportAlcoholism, clinical and experimental research2018

Pharmacogenetic Effects of Naltrexone in Individuals of East Asian Descent: Human Laboratory Findings from a Randomized Trial.

Lara A Ray, ReJoyce Green, Daniel J O Roche, Spencer Bujarski, Emily E Hartwell, Aaron C Lim, Taylor Rohrbaugh, Dara Ghahremani, Kent Hutchison, Karen Miotto

Open access · greenAbstract readRandomized Controlled Trial
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Alcoholism, clinical and experimental research, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.

0numbers the graph read from it
0cells of the map it votes in
14citing papers in PubMed
1.6field-weighted citation impact, top 19% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

14 citing papers in PubMed, 16 citations in OpenAlex.

  1. Trial
  2. Trial
  3. Trial
  4. Article
  5. Article
  6. Review
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Pharmacogenetics of alcohol use disorder treatments: an update.Expert opinion on drug metabolism & toxicology · 2019
    Review
  13. Article
  14. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 2 institutions in 1 country.

Lara A RayDepartment of Psychology, University of California, Los Angeles, Los Angeles, California.
ReJoyce GreenDepartment of Psychology, University of California, Los Angeles, Los Angeles, California.
Daniel J O RocheDepartment of Psychology, University of California, Los Angeles, Los Angeles, California.ORCID 0000-0001-6298-1519
Spencer BujarskiDepartment of Psychology, University of California, Los Angeles, Los Angeles, California.
Emily E HartwellDepartment of Psychology, University of California, Los Angeles, Los Angeles, California.
Aaron C LimDepartment of Psychology, University of California, Los Angeles, Los Angeles, California.
Taylor RohrbaughDepartment of Psychology, University of California, Los Angeles, Los Angeles, California.
Dara GhahremaniDepartment of Psychiatry and Biobehavioral Sciences, University of California, Los Angeles, Los Angeles, California.
Kent HutchisonDepartment of Psychology, University of Colorado, Boulder, Colorado.
Karen MiottoDepartment of Psychiatry and Biobehavioral Sciences, University of California, Los Angeles, Los Angeles, California.
University of California, Los Angeles · USUniversity of Colorado Boulder · US

Funding

UCLA Clinical and Translational Science InstituteUL1TR000124 · NCATS · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI DUBINETT, STEVEN M. · 2012 to 2015
$57.0M
UCLA CLINICAL AND TRANSLATIONAL SCIENCE INSTITUTEUL1RR033176 · NCRR · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI DUBINETT, STEVEN M. · 2011 to 2011
$15.5M
UCLA Training Program in Translational Neuroscience of Drug Abuse (TNDA)T32DA024635 · NIDA · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI LARA A. RAY, Kate M Wassum · 2008 to 2026
$6.2M
Optimizing Naltrexone for Individuals of East Asian DescentR01AA021744 · NIAAA · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI RAY, LARA A. · 2013 to 2015
$1.3M
Subjective Response and Self-Administration of Alcohol in the Human LabF31AA022569 · NIAAA · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI BUJARSKI, SPENCER · 2014 to 2015
$69k
NCATS NIH HHS UL1 TR000124NCRR NIH HHS UL1 RR033176NIAAA NIH HHS F31 AA022569NIAAA NIH HHS R01 AA021744NIDA NIH HHS T32 DA024635
6 · The paper itself

Abstract

backgroundGenetic variation in the endogenous opioid system has been identified as 1 potential source of individual variability in naltrexone treatment outcomes. The majority of naltrexone pharmacogenetic studies have focused on a particular single nucleotide polymorphism (SNP) of the mu-opioid receptor gene (OPRM1; rs1799971; commonly known as the Asn40Asp SNP) in Caucasian samples with decidedly mixed results. The goal of this study was to test the pharmacogenetic effects of naltrexone on subjective response to alcohol and self-administration of alcohol in individuals of East Asian descent. We hypothesized that naltrexone, compared with placebo, would potentiate the aversive and sedative effects of alcohol and reduce alcohol self-administration to a greater extent in Asp40 carriers.

methodsParticipants (N = 77; Asn40Asn, n = 29; Asn40Asp, n = 34, and Asp40Asp, n = 14) completed 2 double-blinded and counterbalanced experimental sessions: one after taking naltrexone (50 mg/d) for 5 days and one after taking matched placebo for 5 days. In each experimental session, participants received a priming dose of intravenous alcohol up to the breath alcohol concentration target of 0.06 g/dl which was immediately followed by an alcohol self-administration period (1 hour).

resultsThere were no pharmacogenetic effects observed for alcohol-induced stimulation, sedation, craving for alcohol, or alcohol self-administration in the laboratory. During the self-administration period, Asp40 carriers consumed fewer drinks and had a longer latency to first drink as compared to Asn40 homozygotes.

conclusionsThese findings in East Asians add to the mixed literature on naltrexone pharmacogenetics from predominantly Caucasian samples and highlight the complexity of these effects and their overall limited replicability. It is plausible that a consistent pharmacogenetic effect in tightly controlled preclinical and experimental medicine models "fades" in more complex and heterogeneous settings and samples.

Indexed as

Alcohol DrinkingAdultAlcohol DeterrentsAsian PeopleCentral Nervous System DepressantsCravingDouble-Blind MethodEthanolFemaleHumansMaleNaltrexonePharmacogenomic TestingPolymorphism, Single NucleotideReceptors, Opioid, muSelf AdministrationAlcohol DeterrentsCentral Nervous System DepressantsEthanolNaltrexoneOPRM1 protein, humanReceptors, Opioid, muAlcohol Use DisorderHuman LaboratoryNaltrexoneNCT02026011Pharmacogenetics

Identifiers

PMID29265379
PMCPMC6086578
OpenAlexW2779153043

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.